Rimegepant
Rimegepant is a pharmaceutical drug with 37 clinical trials. Currently 9 active trials ongoing. Historical success rate of 85.0%.
Success Metrics
Based on 17 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
10
Mid Stage
18
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.0%
17 of 20 finished
15.0%
3 ended early
9
trials recruiting
37
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Clinical Trials (37)
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Acute Migraine Treatment in the ED With Gepants
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
Cluster Headache Treatment With Rimegepant
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
Migraine Medication Effects on Urinary Symptoms
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 37